Literature DB >> 29889114

CORR Insights®: Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.

Bruno Fuchs1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29889114      PMCID： PMC6437573          DOI： 10.1097/01.blo.0000540061.16243.f9

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.176


× No keyword cloud information.
  20 in total

Review 1.  Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.

Authors:  Carl A K Borrebaeck
Journal:  Nat Rev Cancer       Date:  2017-02-03       Impact factor: 60.716

2.  Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward.

Authors:  Joanne P Lagmay; Mark D Krailo; Ha Dang; AeRang Kim; Douglas S Hawkins; Orren Beaty; Brigitte C Widemann; Theodore Zwerdling; Lisa Bomgaars; Anne-Marie Langevin; Holcombe E Grier; Brenda Weigel; Susan M Blaney; Richard Gorlick; Katherine A Janeway
Journal:  J Clin Oncol       Date:  2016-07-11       Impact factor: 44.544

3.  Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Authors:  Brendan Murphy; Han Yin; John M Maris; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; Stephen T Keir; Raushan T Kurmasheva; Igor Dvorchik; Jianrong Wu; Catherine A Billups; Nana Boateng; Malcolm A Smith; Richard B Lock; Peter J Houghton
Journal:  Cancer Res       Date:  2016-08-05       Impact factor: 12.701

4.  Cancer models: The next best thing.

Authors:  Mark A Murakami; David M Weinstock
Journal:  Nature       Date:  2017-08-30       Impact factor: 49.962

5.  Metastasis of cancer: when and how?

Authors:  W-C Lee; S Kopetz; I I Wistuba; J Zhang
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

Review 6.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

Review 7.  Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Authors:  I S Batth; A Mitra; S Manier; I M Ghobrial; D Menter; S Kopetz; S Li
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

8.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

9.  Integrative clinical genomics of metastatic cancer.

Authors:  Dan R Robinson; Yi-Mi Wu; Robert J Lonigro; Pankaj Vats; Erin Cobain; Jessica Everett; Xuhong Cao; Erica Rabban; Chandan Kumar-Sinha; Victoria Raymond; Scott Schuetze; Ajjai Alva; Javed Siddiqui; Rashmi Chugh; Francis Worden; Mark M Zalupski; Jeffrey Innis; Rajen J Mody; Scott A Tomlins; David Lucas; Laurence H Baker; Nithya Ramnath; Ann F Schott; Daniel F Hayes; Joseph Vijai; Kenneth Offit; Elena M Stoffel; J Scott Roberts; David C Smith; Lakshmi P Kunju; Moshe Talpaz; Marcin Cieślik; Arul M Chinnaiyan
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962

Review 10.  Tumour heterogeneity and the evolution of polyclonal drug resistance.

Authors:  Rebecca A Burrell; Charles Swanton
Journal:  Mol Oncol       Date:  2014-07-10       Impact factor: 6.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.